Thomas A. Ollila

Hematology

593 Eddy St
Providence, RI 02903

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study.

Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study.

Journal: Blood advances

Published: November 17, 2025

Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.

Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.

Journal: Blood advances

Published: November 17, 2025

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Journal: Blood

Published: November 13, 2025

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Journal: Blood

Published: September 02, 2025

Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.

Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.

Journal: Haematologica

Published: August 12, 2025

Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.

Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.

Journal: British journal of haematology

Published: June 17, 2025

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Journal: Cancers

Published: May 28, 2025

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Journal: Blood advances

Published: May 09, 2025

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Journal: Blood advances

Published: April 24, 2025

Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study.

Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study.

Journal: Blood cancer journal

Published: December 23, 2024

Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review.

Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review.

Journal: The Lancet. Haematology

Published: November 12, 2024

Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study.

Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study.

Journal: Blood neoplasia

Published: September 18, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026